TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate QR-110 in Leber's Congenital Amaurosis (LCA) Due to the c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, ≥ 6 years of age at Screening with a clinical diagnosis of LCA and a molecular diagnosis of homozygosity or compound heterozygosity for the CEP290 p.Cys998X mutation.~* Best-corrected visual acuity greater than or equal to light perception in both eyes and equal to or worse than LogMAR +1.0 (Snellen notation 20/200) in the worse eye and equal to or worse than LogMAR +0.7 (Snellen notation 20/100) in the contralateral eye.~* Detectable outer nuclear layer (ONL) in the area of the macula.~* An electroretinogram (ERG) result consistent with LCA.~* Clear ocular media and adequate pupillary dilation to permit good quality retinal imaging.~Exclusion Criteria:~* Syndromic disease.~* Pregnant or breast-feeding female.~* Any clinically significant cardiac disease or defect.~* One or more coagulation parameters outside of the normal range.~* Any ocular disease or condition that could compromise treatment safety, visual acuity or interfere with assessment of efficacy and safety.~* Prior receipt of intraocular surgery or intravitreal injection within 3 months prior to study start or planned intraocular surgery or procedure during the course of the study.~* Use of any investigational drug or device within 90 days or 5 half-lives of Day 1, whichever is longer, or plans to participate in another study of a drug or device during the PQ-110-001 study period.~* Any prior receipt of genetic therapy for LCA

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- QR-110 (Type: EXPERIMENTAL): Administered every 3 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Medication Development in Alcoholism: Investigating Glucocorticoid Antagonists

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female volunteers, 18-65 years of age~* Meets Diagnostic and Statistical Manual of Mental Disorders Fourth Addition (DSM-IV) criteria for current alcohol dependence~* Subjects will not be seeking treatment because the medication studies are not treatment trials~* Subjects must be abstinent a minimum of 3 days (but not more than 7 days) prior to the human lab session~* Negative Breath Alcohol Concentration (BAC) and a Clinical Institute Withdrawal Assessment-Alcohol (CIWA-A) score of \< 8 at screening and time of lab session to eliminate acute alcohol or withdrawal effects on dependent measures~* Subjects must be able to complete and understand questionnaires and study procedures in English and sign an informed consent~Exclusion Criteria:~* Significant medical disorders that will increase potential risk or interfere with study participation as determined by the Study Physician~* Female subjects with childbearing potential who are pregnant, nursing, or refuse to use double barrier (non-hormonal) methods of birth control for the duration of the study and one month thereafter~* Meets DSM-IV criteria for a major Axis I disorder including mood or anxiety disorders or substance dependence disorders other than alcohol or nicotine dependence~* History of allergy or hypersensitivity to the study drugs or the ingredients~* Treatment within the month prior to screening with 1.) an investigational drug or vaccine; 2.) drugs that may influence study outcomes, e.g., disulfiram (Antabuse), naltrexone (ReVia), acamprosate (Campral), anticonvulsants, antidepressants.~* In need of or currently taking any psychoactive medications.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Korlym (mifepristone) (Type: ACTIVE_COMPARATOR): 600 mg daily taken orally for one week
- Sugar Pill (Type: PLACEBO_COMPARATOR): placebo pill daily taken orally for one week

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Marijuana Use, Strength Training, and Alcohol Consumption (MUSTAC) Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 21 years;~* English-speaking~* Self-identify as White/Caucasian or Black/African American~* Own a smartphone with cellular/data plan~* Regularly co-use alcohol and smoked marijuana as indicated by scores of ≥3 on item 1 of the CUDIT-R and AUDIT.~* Willing and able to give informed consent~Exclusion Criteria:~* Participation in biceps-specific conditioning program in the past 6 months\*~* Self-reported wrist/hand, elbow, or shoulder pain the past 3 months~* Chronic medical condition that may affect pain perception (e.g. diabetes, fibromyalgia, headaches)~* Self-reported kidney dysfunction, muscle damage, or major psychiatric disorder~* Medical marijuana prescription~* Consumption of marijuana using only non-inhalational methods (e.g. edibles, tinctures, or cannabidiol oil)~* Score of ≥ 10 on Patient Health Questionnaire-9 (moderate depression)~* Women who are pregnant, trying to become pregnant, or breastfeeding

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Delayed Onset Muscle Soreness Induction (Type: EXPERIMENTAL): Participants will complete an exercise session designed to induce delayed onset muscle soreness in the biceps
- Sham Delayed Onset Muscle Soreness Induction (Type: SHAM_COMPARATOR): Participants will complete an exercise session that is unlikely to induce delayed onset muscle soreness in the biceps

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sofosbuvir + Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 or 3 Hepatitis C Infection Who Are Interferon Intolerant, Interferon Ineligible or Unwilling to Take Interferon

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Infection with HCV genotype 2 or 3~* Cirrhosis determination~* Subject meets one of the following classifications:~  1. IFN unwilling~ 2. IFN ineligible~ 3. IFN intolerant~* Screening laboratory values within defined thresholds~* Subject has not been treated with any investigational drug or device within 30 days of the Screening visit~* Use of highly effective contraception methods if female of childbearing potential or sexually active male~Exclusion Criteria:~* Prior exposure to an direct-acting antiviral targeting the HCV nonstructural protein (NS)5B polymerase~* Pregnant or nursing female or male with pregnant female partner~* Current or prior history of clinical hepatic decompensation~* History of clinically-significant illness or any other major medical disorder that may interfere with subject treatment, assessment or compliance with the protocol~* Excessive alcohol ingestion or significant drug abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SOF+RBV (Type: EXPERIMENTAL): Participants were randomized to receive SOF+RBV for 12 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Participants were randomized to receive placebo to match SOF plus placebo to match RBV for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who participated in the placebo arm of a TMC435 study who did not achieve undetectable HCV RNA levels at end of treatment or who relapsed within 1 year after end of treatment OR Patients who received short-term direct-acting antiviral therapy in a Tibotec-sponsored study.~* Liver disease stage documented by liver biopsy is required within 3 years prior to screening unless contraindicated.~Exclusion Criteria:~* Infection with human immunodeficiency virus.~* Liver disease not related to hepatitic C infection.~* Significant laboratory abnormalities or other active diseases.~* Pregnant or planning to become pregnant.~* Prematurely stopped medication in previous TMC435 study for non-compliance or for safety reasons.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- TMC435 (Type: EXPERIMENTAL): TMC435 Type=exact number unit=mg number=150 form=capsule route=oral use once daily for 12 weeks in addition to peginterferon alfa-2a peginterferon and ribavirin for 24 or 48 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics of KBP-5074 in Patients With Moderate Hepatic Impairment

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Males or females, of any race, between 18 and 80 years of age, inclusive, at screening.~2. Body mass index between 18.0 and 40.0 kg/m2, inclusive, at screening.~3. Subjects with normal hepatic function must be in good health.~4. Subjects must meet the criteria for moderate hepatic impairment based on Child Pugh B.~Key Exclusion Criteria:~1. Significant history or clinical manifestation of any medical history, as determined by the investigator not appropriate to participate in this study.~2. Positive serology test results for hepatitis B surface antigen and/or human immunodeficiency virus 1/2.~3. Participation in a clinical study involving administration of an investigational drug (new chemical entity) in the past 30 days or 5 half-lives prior to dosing, whichever is longer.~4. Use of mineralocorticoids or MRAs (eg, spironolactone or eplenerone) within 90 days prior to study drug administration, unless deemed acceptable by the medical monitor and sponsor.~5. Subject has used prescription drugs within 30 days of study drug administration, with the exception of established therapy for hepatic disease and the treatment of associated disorders that have been stable for at least 30 days before study drug administration, as approved by the investigator and in consultation with the medical monitor.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Hepatic Impaired (Type: EXPERIMENTAL): KBP-5074 0.5mg tablet orally, Single dose
- Matched-control Healthy (Type: EXPERIMENTAL): KBP-5074 0.5mg tablet orally, Single dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Bevacizumab Monotherapy in Treatment of Metastatic Melanoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
LEVEL A (second line): after confirmed progression on standard first line treatment with dacarbazine.~LEVEL B (first line): when objective clinical response is observed in LEVEL A, patients will be included for first line treatment with bevacizumab~Inclusion Criteria:~* Histologically confirmed metastatic (unresectable) melanoma and with progressive disease~* WHO performance status 0-2~* Age \>18 years~* Able to undergo outpatient treatment~* Patients must have clinically and/or radiographically documented measurable disease according to RECIST criteria~* At least 4 weeks since adjuvant interferon alpha~* Recovered from prior chemotherapy~* Major surgical procedure or significant traumatic injury within 28 days prior to study treatment start. Biopsy or fine needle aspiration within 5 days prior to study treatment start. Central venous line placement must be inserted at least 5 days prior to treatment start.~* Minimum required laboratory data:~Hematology: absolute granulocytes \> 1.0 x 109/L platelets \> 100 x 109/L Biochemistry: bilirubin \< 1.5 x upper normal limit serum creatinine within normal limits INR \< 1.5~* Before patient registration/randomization, written informed consent must be given according to national and local regulations.~Exclusion Criteria:~* No pregnant or lactating patients can be included~* No prior interferon alpha or IL-2 for metastatic disease~* No more than 1 prior chemotherapy regimen for metastatic disease~* No clinical evidence of coagulopathy~* No brain metastases~* No symptomatic congestive heart failure~* No unstable angina pectoris~* No cardiac arrhythmia~* No history of thrombosis~* No full-dose oral coumarin-derived anticoagulants (INR\>1.5) or heparin, thrombolytic agents, or chronic, daily treatment with aspirin (\>325 mg/day)~* No non-steroidal anti-inflammatory medications (those known to inhibit platelet function at doses used to treat chronic inflammatory diseases)~* No uncontrolled hypertension~* Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Active drug

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity Bridge Between an Investigational Monovalent Vaccine and the Equivalent Component of Gardasil (V501) a Quadrivalent Vaccine (V501-012)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Female with an intact uterus with lifetime history of 0-4 sexual partners~Exclusion Criteria:~* Prior Human Papillomavirus Vaccine (HPV) vaccination;~* Prior abnormal paps;~* Prior history of genital warts

- Gender: FEMALE
- Minimum Age: 16 Years
- Maximum Age: 23 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: StrataGraft® Skin Tissue in the Promotion of Autologous Skin Regeneration of Complex Skin Defects Due to Thermal Burns That Contain Intact Dermal Elements

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria~Subject-specific criteria:~1. Men and women aged ≥ 18 years~2. Written informed consent~3. Sufficient healthy skin identified and reserved as a donor site in the event that the StrataGraft treatment site requires autografting~4. Clinical expectation that the study donor site will heal without grafting~5. Complex skin defects of 3-49% TBSA~   * Total burn may consist of more than one area~   Treatment site-specific criteria:~6. Thermal burn(s) with intact dermal elements for which excision and autografting are clinically indicated~7. Total of both study treatment areas can be up to 2000 cm2~8. First excision and grafting of study treatment sites~9. Thermal burn(s) on the torso, arms, or legs~Exclusion Criteria~Subject-specific criteria:~1. Pregnant women~2. Prisoners~3. Subjects receiving systemic immunosuppressive therapy~4. Subjects with a known history of malignancy~5. Preadmission insulin-dependent diabetic subjects~6. Subjects with concurrent conditions that in the opinion of the investigator may compromise subject safety or study objectives~7. Expected survival of less than three months~8. Participation in the treatment group of an interventional study within 90 days prior to enrollment~   Treatment site-specific criteria:~9. Full-thickness burns~10. Chronic wounds~11. The face, head, neck, hands, feet, buttocks, and area over joints~12. Treatment sites immediately adjacent to unexcised eschar~13. Clinical or laboratory determination of infection at the anticipated treatment sites

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- StrataGraft Skin Tissue (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Olanzapine in the Treatment of Hair Pulling (Trichotillomania)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* primary DSM-IV trichotillomania; CGI-Severity ≥ 4~Exclusion Criteria:~* Any other Axis I primary diagnosis; CGI-S \< 4; current comorbid: OCD, MDD, alcohol or substance abuse; lifetime hx of: schizophrenia, bipolar affective disorder or dementia; current pregnancy/lactation; current suicidality or homicidality; major medical problems or clinically unstable medical disease; hx of: seizures, stroke or head trauma; prior use of neuroleptics

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Ciclesonide Inhaled Once Daily Versus Other Corticosteroids Used for Treatment of Mild Asthma in Children (4 to 11 Years) (BY9010/CA-101)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Main Inclusion Criteria:~* Outpatients~* Symptoms consistent with the diagnosis of asthma for at least 12 months~* Forced Expiratory Volume in one Second (FEV) at least 80% of predicted~* Participants who have a history of reversible airway obstruction~* Good health with the exception of asthma~Main Exclusion Criteria:~* History of life-threatening asthma~* A hospitalization for asthma within the last 3 months, or more than two hospitalizations for asthma within the last year~* Concomitant severe diseases or diseases which are contraindications for the use of inhaled steroids~* Participants suffering from relevant lung diseases causing alternating impairment in lung function (e.g. chronic bronchitis or emphysema)~* Prematurely born children (\<36 weeks of gestation)~* Smokers~* Pregnancy (or intention to become pregnant during the course of the trial), breast feeding or lack of safe contraception by female of child-bearing potential

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- Ciclesonide 100 µg (Type: ACTIVE_COMPARATOR): Ciclesonide 100 µg, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.
- Ciclesonide 200 µg (Type: ACTIVE_COMPARATOR): Ciclesonide 200 µg, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Does Local Morphine Add to Local Anesthetics in Serratus Anterior Plane Block Has a System Analgesic Effect?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* (ASA) class I-II~* body weight of 50 - 90 kg~Exclusion Criteria:~* a history of bleeding diathesis,~* relevant drug allergy, opioid dependence,~* sepsis, prior surgery in the supraclavicular, infraclavicular or axillary regions, alcohol or drug abuse , patients with advanced cardiovascular disease

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- morphine sulphate (Type: ACTIVE_COMPARATOR): 10mg locally morphine hydrochloride once betwwen serratus muscle and latissmus dorsi muscle
- bupivacaine hydrochloride (Type: PLACEBO_COMPARATOR): 0.25%locally bupivacaine hydrochloride once

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete